Elias Jabbour
YOU?
Author Swipe
View article: Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia Open
View article: 101 Trends in antenatal risk factors and the cumulative effect on outcomes of very preterm infants in Canada 2010-2023
101 Trends in antenatal risk factors and the cumulative effect on outcomes of very preterm infants in Canada 2010-2023 Open
Background Antenatal risk factors such as maternal diabetes, maternal hypertension, maternal age at birth and lower socioeconomic status (income and education) have been increasing over time in high-income countries. Antenatal factors are …
View article: A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias Open
View article: Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies Open
Clinical Trial Protocol
View article: Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies Open
Hepatic adverse events
View article: Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies Open
Study population representation table
View article: Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies Open
Supplementary protocol for "Phase Ib/II Investigator Initiated Study of the IDH1-mutant inhibitor ivosidenib (AG120) with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies"
View article: Mixed‐Phenotype Acute Leukemia With Mutated <i>TP53</i> : Genetic Landscape, Therapeutic Response, and Outcomes
Mixed‐Phenotype Acute Leukemia With Mutated <i>TP53</i> : Genetic Landscape, Therapeutic Response, and Outcomes Open
View article: Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations
Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations Open
Objective Bleximenib is a potent, selective menin inhibitor with activity in NPM1-mutated (NPM1m)or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML), now in Phase 3 development in combination with AML-directed therapies. Previous dat…
View article: Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial
Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial Open
Background: The standard of care treatment for patients with high-risk myelodisplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML) are hypomethylating agents (HMA). Hematopoietic stem-cell transplantation (HSCT) is the on…
View article: Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL
Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL Open
Introduction: The treatment landscape of chronic lymphocytic leukemia (CLL) includes Bruton tyrosine kinase inhibitors (BTKi), B-cell lymphoma 2 (BCL2) inhibitor and CD20 monoclonal antibodies (mAb). Several studies explored the safety and…
View article: Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor
Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor Open
Introduction Some patients (pts) with chronic myeloid leukemia (CML) eventually develop disease resistance or treatment intolerance after first-line therapy (1L) with a second-generation tyrosine kinase inhibitor (2G-TKI). Second-line ther…
View article: Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center
Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center Open
Introduction: The Area Deprivation Index (ADI), which measures neighborhood disadvantage using 17 socioeconomic factors, is a well-validated tool for assessing health equity (Powell et al., Forefront, 2023). ADI is an independent prognosti…
View article: Use and outcomes following blinatumomab rechallenge in adolescents and young adults (AYA) and adults with B-cell acute lymphoblastic leukemia (B-ALL)
Use and outcomes following blinatumomab rechallenge in adolescents and young adults (AYA) and adults with B-cell acute lymphoblastic leukemia (B-ALL) Open
Introduction: Adults and AYA patients (pts) with relapsed/refractory (R/R) B-ALL have a poor prognosis, despite new therapies approved since 2015. After each relapse, R/R B-ALL becomes more difficult to treat due to its aggressiveness, acq…
View article: Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia
Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia Open
Background: Core binding factorfactor (CBF) leukemias are defined by presence of unique translocation events; t(8;21)(RUNX1::RUNX1T1) or inv(16)/t(16;16) (CBFB:: MYH11) and are thus amenable for quantitative polymerase chain reaction (qPCR…
View article: Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens
Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens Open
Hyperglycemia is a well-recognized complication of induction chemotherapy in patients with B cell acute lymphoblastic leukemia (B-ALL). Due to the use of high dose dexamethasone, induction chemotherapy frequently leads to worsening of hype…
View article: A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens Open
Advances in the prognostication, monitoring, and treatment of both the acute and chronic leukemias have led to drastically improved outcomes over the past 2 decades. With the advent of targeted therapies, including antibodies such as blina…
View article: Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL Open
Baseline cytomolecular features and measurable residual disease (MRD) dynamics are both strongly prognostic in acute lymphoblastic leukemia (ALL). Whether early MRD response can overcome the adverse prognosis of high-risk (HR) cytomolecula…
View article: The effectiveness, cost-effectiveness, budget impact, and return on investment of scaling up tuberculosis screening and preventive treatment in Brazil, Georgia, Kenya, and South Africa: a modelling study
The effectiveness, cost-effectiveness, budget impact, and return on investment of scaling up tuberculosis screening and preventive treatment in Brazil, Georgia, Kenya, and South Africa: a modelling study Open
World Health Organization.
View article: PHASE Ib PILOT STUDY OF ITACITINIB WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA
PHASE Ib PILOT STUDY OF ITACITINIB WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA Open
View article: Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline <scp>FLT3</scp> Inhibitor‐Based Therapy in <scp> <i>FLT3</i> </scp> ‐Mutated <scp>AML</scp>
Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline <span>FLT3</span> Inhibitor‐Based Therapy in <span> <i>FLT3</i> </span> ‐Mutated <span>AML</span> Open
View article: Estimated costs of tuberculosis services in Brazil, 2023
Estimated costs of tuberculosis services in Brazil, 2023 Open
Introduction To eliminate tuberculosis (TB) in Brazil, scaling up screening and prevention strategies will be essential. We estimated costs of TB services in Brazil to support budgeting, cost-effectiveness analysis and inform the implement…
View article: Costs of 4 Months of Rifampin Versus 2 Months of Double-dose Rifampin for Tuberculosis Infection: Post-Hoc Analysis of a Phase 2b Randomized Trial
Costs of 4 Months of Rifampin Versus 2 Months of Double-dose Rifampin for Tuberculosis Infection: Post-Hoc Analysis of a Phase 2b Randomized Trial Open
Background Cost is an important consideration when implementing tuberculosis preventive treatment regimens (TPT). We used data from a phase 2b randomized trial of TPT to estimate overall cost and key drivers of costs for two TPT regimens. …
View article: Outcomes and Patterns of Relapse of <scp> <i>NPM1</i> </scp> Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies
Outcomes and Patterns of Relapse of <span> <i>NPM1</i> </span> Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies Open
View article: Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With <scp> <i>KMT2A</i> </scp> Rearrangements Treated With Immunotherapy‐Based Regimens
Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With <span> <i>KMT2A</i> </span> Rearrangements Treated With Immunotherapy‐Based Regimens Open
View article: Contemporary outcomes of octa‐nonagenarians with newly diagnosed acute myeloid leukemia
Contemporary outcomes of octa‐nonagenarians with newly diagnosed acute myeloid leukemia Open
Background Octa‐nonagenarians with acute myeloid leukemia (AML) represent a high‐risk group due to frequently poor performance status, adverse genomics (e.g., TP53 mutations, complex karyotype), a high incidence of secondary AML, and inabi…
View article: Mini-Hyper-CVD plus Venetoclax and Navitoclax for Relapsed/Refractory Acute Lymphoblastic Leukemia
Mini-Hyper-CVD plus Venetoclax and Navitoclax for Relapsed/Refractory Acute Lymphoblastic Leukemia Open
View article: Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies Open
Table S1: Pharmacokinetics of IVO+VEN and IVO+VEN+AZATable S2: Treatment characteristics across the four dose levels in the phase 1b study population.Table S3: Study medication adherence: (A), Adherence to protocol administered medications…
View article: Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies Open
Supplementary protocol for "Phase Ib/II Investigator Initiated Study of the IDH1-mutant inhibitor ivosidenib (AG120) with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies"
View article: Management of chronic myeloid leukemia in 2025
Management of chronic myeloid leukemia in 2025 Open
Chronic myeloid leukemia (CML) has an annual incidence of approximately two cases per 100,000. The reduction in annual mortality from 10%–20% to 1% with BCR::ABL1 tyrosine kinase inhibitors (TKIs) has resulted in an increased prevalence in…